This press release by TherapeuticsMD, Inc. To learn more about TherapeuticsMD, please visit or follow us on Twitter: and on Facebook: TherapeuticsMD. The company is committed to advancing the health of women and championing awareness of their healthcare issues. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. The inducement grant was approved on Octoby a majority of the independent directors of the Company’s Board of Directors in reliance on the employment inducement exception to shareholder approval provided under NASDAQ Stock Market Listing Rule 5635(c)(4).
The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. Glickman’s continuous service with the Company. The PSUs will vest based on certain performance metrics related to revenue and the timing in which the Company achieves EBITDA break even, and are subject to Mr. 400,000 of the RSUs will vest at the end of three years, and 260,000 of the RSUs will vest in equal annual installments over three years beginning October 15, 2022, in each case subject to Mr. Glickman an award of 660,000 restricted stock units (“RSUs”) and 260,000 performance stock units (“PSUs”) corresponding to shares of common stock of the Company, outside of the Company’s 2019 Stock Incentive Plan (the “2019 Plan”). Glickman’s acceptance of the appointment, TherapeuticsMD granted Mr. Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Īs a material inducement to Mr. Glickman received his MBA in Finance and International Management from New York University and his BA from State University of New York College at Oswego. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceuticals, and Executive Vice President, Sales and Marketing, of Auxilium Pharmaceuticals, among other global pharmaceutical roles. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Mark Glickman as the Company’s Chief Business Officer. TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business OfficerīOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. Auxilium also has programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite. Among other products in the U.S., Auxilium markets edex (alprostadil for injection), an injectable treatment for erectile dysfunction, Osbon ErecAid, the leading device for aiding erectile dysfunction, STENDRA (avanafil), an oral erectile dysfunction therapy, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy, XIAFLEX (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture, Testim (testosterone gel) for the topical treatment of hypogonadism and an Authorized Generic version of Testim (testosterone gel) with its partner Prasco. Auxilium now has a broad portfolio of 12 approved products. With a broad range of first- and second-line products across multiple indications, Auxilium is an emerging leader in the men's healthcare area and has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas.
Auxilium Pharmaceuticals is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences.
0 kommentar(er)
